A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder

S. A. Montgomery, A. McIntyre, M. Osterheider, P. Sarteschi, W. Zitterl, J. Zohar, M. Birkett, A. J. Wood

Research output: Contribution to journalArticlepeer-review

Abstract

We have studied the effect of three fixed daily doses of fluoxetine in patients with obsessive-compulsive disorder (OCD) diagnosed according to DSM-III-R. Two hundred and fourteen patients were evaluated in an 8-week double blind, placebo-controlled study. A statistically significantly greater number of fluoxetine-treated patients achieved the prospectively defined criteria for clinical response when compared to placebo treatment. There was a statistically significant overall difference in the PGI rating of symptom change (P = 0.045) and a marginally significant difference (P = 0.089) in the CGI severity rating between groups. Pairwise comparison against placebo showed a marginally statistically significantly greater improvement (P = 0.059) in Y-BOCS-Total score for patients receiving fluoxetine 60 mg daily, and a significantly higher response rate in patients receiving fluoxetine 40 mg or 60 mg daily (P<0.05). One hundred and sixty one patients continued to a 16-week extension evaluation. There was no significant difference in the rate of reporting of any individual adverse event between placebo and fluoxetine, and the rate of discontinuation due to adverse events was low (< 6% in each study phase). This study supports the growing evidence for the safety and efficacy of fluoxetine in the treatment of OCD.

Original languageEnglish
Pages (from-to)143-152
Number of pages10
JournalEuropean Neuropsychopharmacology
Volume3
Issue number2
DOIs
StatePublished - Jun 1993
Externally publishedYes

Keywords

  • Double-blind
  • Fluoxetine
  • Obsessive-compulsive disorder
  • Placebo

Fingerprint

Dive into the research topics of 'A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder'. Together they form a unique fingerprint.

Cite this